Department profile
Mintz

Life Sciences

USA Guide 2026 : USA - Nationwide


Mintz

About

Provided by Mintz

Mintz’s Life Sciences practice is a multidisciplinary team of more than 250 attorneys and professionals advising companies, investors, and institutions at the intersection of scientific innovation, intellectual property, capital formation, and regulatory strategy. The firm represents leading pharmaceutical and biotechnology companies, including Amgen, Eli Lilly, Sanofi, QIAGEN, and Fulgent Genetics, as well as prominent life sciences investors and financial institutions.

The practice is built on the premise that value in the life sciences sector is driven by the strategic alignment of intellectual property, capital planning, and regulatory execution across a company’s full lifecycle. Mintz advises clients from early development through commercialization, enforcement, and exit, providing integrated guidance as financing structures, collaboration models, and competitive pressures continue to evolve.

Chambers Review

Provided by Chambers

Life Sciences - USA - Nationwide

Band 4

Band 4


What the Team is Known For

Mintz has an extensive practice advising companies on a wealth of transactional matters in the life sciences sector. The team at Mintz is well equipped to provide support and guidance relating to M&A, private equity financings, initial public offerings, collaboration and licensing agreements, business combinations and SPAC deals. They are also recognized for their experience in managing patent families, as well as their strengths in IP strategy and due diligence.

Notable practitioners

William Hicks is a key contact.

Work Highlights

Provided by Chambers

  • Mintz continued to represent Amgen in multiple BPCIA litigation matters to protect its biologics, Prolia and XGEVA, from biosimilar competition.

Mintz has rankings in the following guides

What success is built on

Chambers is the leading data and intelligence partner for the legal sector.

Explore thought leadership